Pharmaceutical Technology

APRIL 5, 2024

Caris Life Sciences has entered a collaboration with Merck KGaA for the development of antibody-drug conjugates (ADCs) for cancer.

Development 130

Development Life Science Antibody Drugs 130

Pharmaceutical Technology

JULY 20, 2022

TSB Therapeutics, a joint venture (JV) majority-owned by Brii Biosciences (Brii Bio), has entered a collaboration with China Resources Pharmaceutical Commercial Group (CR Pharma) for the commercialisation of an antibody therapy, amubarvimab/romlusevimab combination, for Covid-19 in China. .

Antibody 147

Antibody Life Science Production Development 147

XTalks

MAY 9, 2024

Genmab, a trailblazer in the field of antibody therapeutics, celebrates this milestone by reflecting on its impressive journey from a small-scale startup to a global leader in cancer treatment and beyond. Since then, innovative science has been at Genmab’s core, as we harness the power of human antibodies to improve the lives of patients.

Antibody 52

Antibody Clinical Trials Clinical Trials Medicine 52

Scienmag

MAY 13, 2022

LA JOLLA, CA—Last year, scientists at Scripps Research and Toscana Life Sciences studied the blood of 14 COVID-19 survivors to find the most potent antibodies against the SARS-CoV-2 virus.

Antibody 100

Antibody Scientist Research Life Science 100

Fierce Pharma

NOVEMBER 30, 2023

The sizzling antibody-drug conjugate (ADC) field is at the center of another major life sciences deal. | The sizzling antibody-drug conjugate field is at the center of another major life sciences deal. Hoping to redeem itself following the epic Rova-T failure, AbbVie is shelling out $10.1

Life Science 131

Life Science Antibody Drugs 131

XTalks

FEBRUARY 23, 2022

The team also talked about Eli Lilly’s new COVID-19 monoclonal antibody bebtelovimab that received emergency use authorization (EUA) from the US Food and Drug Administration (FDA) indicated for patients with mild to moderate COVID-19 who are at risk of progressing to severe disease.

Life Science 52

Life Science Antibody Vaccination Vaccine 52

XTalks

NOVEMBER 2, 2022

In this episode, Ayesha discussed the FDA approval of two new immunotherapies, including Janssen/Johnson & Johnson’s bispecific antibody Tecvayli for the treatment of relapsed or refractory multiple myeloma. The drug is the first bispecific T cell antibody to be approved in the US.

FDA Approval 52

FDA Approval Life Science Antibody Drugs 52

Drug Discovery World

JULY 3, 2023

It’s a challenging time to launch a new company in the life sciences sector. Irvine expands on this further: “Starting a company in life sciences is always challenging. The post Launching a life sciences company: How to stand out from the crowd appeared first on Drug Discovery World (DDW). from 2021 and 54.8%

Life Science 52

Life Science Pharma Companies Drugs Marketing 52

XTalks

OCTOBER 4, 2023

Immunogenicity data from the study showed sustained HPV-antibody responses ten years after administration of the third dose in both boys and girls. Subscribe to the Xtalks Life Science Podcast to never miss a new episode.

Life Science 52

Life Science Vaccination Vaccine Antibody 52

BioTech 365

SEPTEMBER 1, 2021

Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement … Continue reading →

Life Science 52

Life Science Licensing Licensing Antibody 52

Drug Discovery World

APRIL 27, 2023

Biotechnology company Tiziana Life Sciences is initiating a programme to develop intranasal foralumab for the treatment or prevention of type 1 diabetes. We believed that having a fully human CD3 antibody may offer benefits to patients across many different chronic disease indications.”

Antibody 52

Antibody Development Life Science FDA Approval 52

XTalks

DECEMBER 17, 2021

Xtalks is taking a look at some of the major stories and innovations of the year in the life sciences, many of which were driven by new, emerging and improved technologies. The year 2021 was all about continuing innovations in the life sciences. Life Science Innovations: Malaria and Influenza Vaccines.

Life Science 98

Life Science Vaccination Vaccine Trials 98

XTalks

JANUARY 5, 2021

These include monoclonal antibody drugs, which are attractive therapeutic agents owing to their targeted specificity. Eli Lilly’s bamlanivimab and Regeneron’s monoclonal antibody cocktail REGEN-COV2 which consists of two monoclonal antibodies, casirivimab and imdevimab, were approved in 2020 for use in the treatment of COVID-19 patients.

Life Science 98

Life Science Clinical Trials Clinical Trials Trials 98

BioSpace

SEPTEMBER 2, 2020

The use of structured data and automation can accelerate antibody engineering as much as 50%, Prem Mohanty, product marketing manager and life sciences product specialist for Benchling, told BioSpace.

Engineer 89

Engineer Antibody Life Science Production 89

XTalks

AUGUST 10, 2022

Ayesha also talked about the FDA approval of AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC) Enhertu (trastuzumab-deruxtecan) for the treatment of patients with unresectable or metastatic HER2-low breast cancer. Subscribe to the Xtalks Life Science Podcast to never miss a new episode.

Life Science 52

Life Science FDA Approval Drugs Licensing 52

The Pharma Data

MARCH 15, 2022

Global Head of Research and Development for Sanofi “ The collaboration with Blackstone will accelerate our ability to offer patients a subcutaneous anti-CD38 antibody therapy that we believe will be innovative and more convenient. Sarclisa ® is a monoclonal antibody that targets a specific epitope on the CD38 receptor on MM cells.

Life Science 52

Life Science Antibody Clinical Trials Clinical Trials 52

XTalks

AUGUST 18, 2021

Many people with weakened immune systems have been shown to have either low antibody titers, or none at all, after receiving a standard two-dose regimen of the Pfizer and Moderna COVID-19 vaccines. Subscribe to the Xtalks Life Science Podcast to never miss a new episode.

Life Science 52

Life Science Vaccination Vaccine Antibody 52

BioTech 365

JANUARY 4, 2021

Tiziana Life Sciences plc (“Tiziana” or the “Company”) – Tiziana announces completion of the clinical trial with nasally administered Foralumab, its proprietary fully human anti-CD3 monoclonal antibody, for the treatment of COVID-19 patients in Brazil Tiziana Life Sciences plc (“Tiziana” … Continue reading (..)

Life Science 40

Life Science Clinical Trials Clinical Trials Antibody 40

Drug Discovery World

JANUARY 10, 2023

For over 50 years, Bethyl Laboratories (now a Fortis Life Sciences brand) has been dedicated to improving lives by supporting scientific discovery through qualified antibody products and custom services. Antibody validation. Antibody validation. A proposal for validation of antibodies.

Antibody 52

Antibody Protein Reagent Scientist 52

BioSpace

APRIL 3, 2024

Amid a flurry of deals in the antibody-drug conjugate space, Merck KGaA is getting in on the action with a partnership with Caris Life Sciences to accelerate the discovery and development of first-in-class ADCs for oncology.

Life Science 65

Life Science Development Antibody Drugs 65

Drug Discovery World

JULY 18, 2022

Life sciences company Carterra has joined data cloud company TetraScience’s network of partners to help generate insights into the potential of antibodies as drug candidates. . The Tetra Partner Network (TPN) is an ecosystem of partners which connects R&D data for pharmaceutical and biopharmaceutical customers. .

Antibody 52

Antibody Life Science Drugs Development 52

Pharmaceutical Technology

APRIL 14, 2023

TORL BioTherapeutics is a newly formed, US-based company focused on the development of novel antibody-based therapeutics for cancer patients. The first-in-class, clinical-stage antibody-drug conjugate (ADC) targeting Claudin 6 (CLDN 6), TORL-1-23 is being developed to treat patients across several cancer types. CLDN 18.2).

Development 264

Development Clinical Trials Clinical Trials Life Science 264

XTalks

SEPTEMBER 7, 2021

After a two-month long halt, federal officials have given the go-ahead to resume nationwide distribution of Eli Lilly’s COVID-19 monoclonal antibodies bamlanivimab and etesevimab. However, studies now show the COVID-19 monoclonal antibodies can work against the variant. 1 and Beta/B.1.351, 1.351, respectively). “The

Antibody 97

Antibody In-Vitro Drugs Sales 97

BioTech 365

DECEMBER 22, 2020

LSBio Acquires Absolute Antibody Ltd. LSBio Acquires Absolute Antibody Ltd. SEATTLE–(BUSINESS WIRE)–LSBio (LSBio™), a leading provider of antibodies and life science research reagents, is pleased to announce its acquisition of Redcar, UK-based Absolute Antibody, Ltd.

Antibody 52

Antibody Reagent Life Science Research 52

The Pharma Data

JUNE 1, 2022

AstraZeneca’s Chief Executive Officer, Pascal Soriot, today received a British knighthood for services to UK life sciences and leadership in the global response to the COVID pandemic in the Queen’s Birthday Honours 2022. Alongside leading AstraZeneca, Pascal is also driving change across the healthcare sector and beyond.

Life Science 52

Life Science Medicine Vaccination Vaccine 52

The Pharma Data

NOVEMBER 30, 2020

Shailubhai will provide updates on the Company’s proposed move from AIM to the Standard Segment of the Main Market of the London Stock Exchange, ongoing clinical trials, as well as other recent developments in Tiziana Life Sciences. About Tiziana Life Sciences. NEW YORK and LONDON, Dec. +44 (0)20 7495 2379.

Life Science 40

Life Science Antibody Clinical Trials Clinical Trials 40

BioSpace

MARCH 14, 2021

Nearly five years to the day after striking the deal, AVEO Oncology and CANbridge Life Sciences announce the termination of their collaboration and licensing agreement for AVEO’s AV-203.

Life Science 98

Life Science Antibody Licensing Licensing 98

pharmaphorum

JANUARY 12, 2024

Discover the top six key takeaways from JP Morgan's 2024 conference, focusing on dealmaking trends in big tech, life science, AI, and advancements in cell and gene therapies, as well as the future of Antibody-drug conjugates (ADCs). Stay informed with the latest industry insights.

Gene Therapy 59

Gene Therapy Life Science Antibody Gene 59

XTalks

NOVEMBER 3, 2021

The implant is surgically placed in the eye and injected with Genentech’s anti-VEGFA monoclonal antibody ranibizumab for continuous delivery. Subscribe to the Xtalks Life Science Podcast to never miss a new episode. Genentech’s New Ocular Implant Drug Delivery System for Macular Degeneration Could Be a Game Changer.

Life Science 52

Life Science Drug Delivery Systems Vaccination Vaccine 52

BioTech 365

OCTOBER 12, 2021

NanoString Launches nCounter Antibody Drug Conjugate Panel to Accelerate the Development of Oncology Treatments NanoString Launches nCounter Antibody Drug Conjugate Panel to Accelerate the Development of Oncology Treatments SEATTLE–(BUSINESS WIRE)–NanoString Technologies, Inc.

Antibody 52

Antibody Development Life Science Drugs 52

pharmaphorum

JULY 19, 2021

Drugs harnessing the potential of modified RNA, antisense and siRNA oligonucleotides, antibody–drug conjugates and nanomedicines will become as important as today’s ‘small molecule’ drugs, reaching potential market values into the hundreds of billions – if the potential can be realised through innovation support and industry collaboration.

Life Science 52

Life Science Medicine RNA Vaccination 52

XTalks

SEPTEMBER 30, 2020

The research shows that the activity of the immune messenger type 1 interferon (IFN) protein is diminished, either by genetic mutations or an autoimmune attack by neutralizing antibodies against it, in a subset of COVID-19 patients. These rogue antibodies blocked interferon action and were not present in patients with mild COVID-19 cases.

Antibody 135

Antibody Genetics Research In-Vitro 135

The Pharma Data

JANUARY 3, 2021

Dr. Kunwar Shailubhai, CEO and CSO of Tiziana Life Sciences, commented: “While we expect to get the topline data in January 2021, we are delighted with the positive feedback received from the treated patients. About Tiziana Life Sciences. . NEW YORK and LONDON, Jan. +44 (0)20 7495 2379. .

Life Science 40

Life Science Clinical Trials Clinical Trials Antibody 40

BioTech 365

MAY 26, 2021

A New Covid-19 Rapid Test That Can Verify Antibody Response to Any Vaccine MyBio: Has My Vaccine Worked? A New Covid-19 Rapid Test That Can Verify Antibody Response to Any Vaccine Kilkenny based life sciences … Continue reading → MyBio: Has My Vaccine Worked?

Antibody 52

Antibody Vaccination Vaccine Life Science 52

XTalks

JULY 28, 2021

Ayesha and the team talked about the controversial approval of the drug, with lingering questions about its clinical benefit despite having the ability to reduce amyloid plaques as an anti-amyloid monoclonal antibody.

Life Science 52

Life Science FDA Approval Drugs Antibody 52

pharmaphorum

MAY 20, 2021

Switzerland’s Numab has raised 100 million Swiss francs – around $110 million – in Series C financing to develop bispecific antibodies for cancer and inflammation, with Novo Noldings and HBM Partners co-leading the investor syndicate. The post Numab raises $110m to develop cancer bispecific antibodies appeared first on.

Antibody 52

Antibody Development Clinical Development Life Science 52

Drug Discovery World

APRIL 3, 2023

I quickly recognised the commercial value of aptamers as being able to address the gap in the market where antibodies fail to perform, and together we established the business to begin aptamer development. What advantages do they offer over antibodies?   DS: How are aptamers currently used in the development of precision treatments?

Antibody 52

Antibody Gene Therapy Gene In-Vitro 52